At the invitation of the Government of Brazil, the Stop TB Partnership Board held its 37th meeting in Brasilia, Brazil on 6-8 February 2024. The strategic forum was co-hosted locally by the Ministry of Health of Brazil and G20 Health Working Group.

The International Union Against Tuberculosis and Lung Disease released the February 2024 issue of IJTLD OPEN – a fully-compliant, open access journal to enhance the coverage of TB and lung disease.

CAIRNS, Feb 21 – Tuberculosis (TB) is the world’s most deadly infectious disease. But lofty global plans to stamp out this global killer by 2030 were dramatically slowed by the Covid-19 pandemic.

The Stop TB Partnership Working Group on New TB Vaccines (WGNV) released a newsletter with the latest updates related to TB vaccines.

A story tells how the endTB project has improved TB care through a series of scientific studies while pushing the boundaries of what’s thought possible: in clinical trials, in epidemiology, and in the thinking about where you can do the science required to deliver world-class health care where it’s needed most.

Figures published by the UK Health Security Agency (UKHSA) in its TB annual report, show that tuberculosis cases in England in 2022 were stable compared to 2021 (4,380 in 2022 compared to 4,411 in 2021).

LOS ANGELES, Feb. 14, 2024 -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 (Pharmacokinetics and Safety of Double-dose Dolutegravir When Used with Rifapentine for HIV-associated Tuberculosis). A5406 is a phase 2, open-label pharmacokinetic study investigating the effect that the anti-tuberculosis (TB) medication rifapentine has on levels of the HIV medication dolutegravir in the blood of participants who have HIV-associated TB and whether this combination can be safely and effectively used together.

ACTON releases an advocacy tool exploring what funding gaps in the Global Fund’s Grant Cycle 7 mean for the fight against TB and what happens if they are not filled.

There are many reasons why HIV is such a perplexing virus to combat. One of them is that there are incredibly few people — only a few, if that, of the nearly 86 million people to acquire HIV to date — who have naturally cleared the virus after becoming infected. Once an HIV infection occurs, it almost always persists in the body for a lifetime.

The World Health Organization announces forthcoming updates on TB preventive treatment.